Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Centessa Pharmaceuticals ( (CNTA) ) has provided an update.
Centessa Pharmaceuticals has entered into a loan and security agreement with Oxford Finance LLC, securing up to $200 million in term loans to refinance existing debt and support its operations. The initial $110 million loan was used to repay existing obligations under a previous note purchase agreement, and the new agreement includes covenants limiting certain financial actions and securing the loans with a first priority security interest in the company’s assets.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company primarily works on advancing its orexin agonist program, which includes Phase 2 and Phase 3 clinical trials for its lead orexin asset programs.
YTD Price Performance: 112.94%
Average Trading Volume: 531,497
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.23B
See more insights into CNTA stock on TipRanks’ Stock Analysis page.
Trending Articles
- Amazon (NASDAQ:AMZN) Carries on With Grocery Store Plans
- Ford (NYSE:F) Faces Multiple Product Recalls
- ‘Favorable Trends,’ Says Top Investor About Super Micro Computer Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
